Pablo Maroto
A5038937574- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Testicular diseases and treatments
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Advanced Breast Cancer Therapies
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Urologic and reproductive health conditions
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Prostate Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Cancer, Lipids, and Metabolism
- Multiple Myeloma Research and Treatments
- Sexual Differentiation and Disorders
- Sarcoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Genital Health and Disease
- Ovarian cancer diagnosis and treatment
Hospital de Sant Pau
2016-2025
Universitat Autònoma de Barcelona
2002-2025
Institut Claudius Regaud
2024
European Organisation for Research and Treatment of Cancer
2010-2020
Hospital San Juan de la Cruz
2017-2019
University of St. Gallen
2017
St Olav's University Hospital
2017
Vall d'Hebron Hospital Universitari
2006-2016
Institut Català d'Oncologia
2001-2016
Hospital Universitario 12 De Octubre
2016
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared that sunitinib is unclear.
Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well MET and AXL, each of which has been implicated in the pathobiology metastatic renal-cell carcinoma or development resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated efficacy cabozantinib, compared with everolimus, patients had progressed after VEGFR-targeted therapy.We randomly assigned 658 receive cabozantinib at a...
Purpose This is the first randomized phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible (“unfit”) for cisplatin chemotherapy. Patients and Methods The primary objective of III part this study was to compare overall survival (OS) chemotherapy-naive measurable disease an impaired renal function (glomerular filtration rate < 60 but > 30 mL/min) and/or performance score 2 were randomly assigned receive either...
Abstract BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 administered orally at 125 mg/day on 3 weeks on, 1 week off schedule until unacceptable toxicity progression. primary endpoint the response rate. Among...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
To assess the efficacy of a risk-adapted treatment policy for patients with stage I seminoma by using universally accepted risk criteria.Between 1999 and 2003, 314 clinical after orchiectomy were prospectively included. One hundred (31.8%) presented no factors managed surveillance. In contrast, 131 (41.7%) had tumors larger than 4 cm, 33 (10.5%) rete testis involvement, 50 (15.9%) both factors. All latter received two courses adjuvant carboplatin.Chemotherapy was well tolerated, as only 17...
There is no standard treatment for patients with advanced urothelial cancer who are ineligible ("unfit") cisplatin-based chemotherapy (CHT). To compare the activity and safety of two CHT combinations in this patient group, a randomized phase II/III trial was conducted by EORTC (European Organisation Research Treatment Cancer). We report here II results study.CHT-naïve measurable disease impaired renal function (30 mL/min < glomerular filtration rate [GFR] 60 mL/min) and/or performance status...
Purpose To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both risk relapse and proportion receiving adjuvant chemotherapy while maintaining high cure rate. Patients Methods From 2004 2008, 227 were included after orchiectomy in multicenter study. Eighty-four (37%) presented no local factors, 44 (19%) had tumors larger than 4 cm, 25 (11%) rete testis involvement, 74 (33%) criteria. Only latter group received two...
Introduction The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrectomy, and sarcomatoid have been associated disease success. This subsequent analysis explores outcomes in or without specific prognostic features. Methods In CLEAR, clear RCC were randomly...
To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma.Untreated pure seminoma testis after orchiectomy, clinical IIB, were considered eligible for this prospective observational study. Chemotherapy consisted either four cycles cisplatin etoposide three cisplatin, etoposide, bleomycin.Between April 1994 March 2003, 72 entered onto study at 26 participating centers. Eighteen had disease, 54 disease....
Purpose Pneumonitis has occurred in patients treated with inhibitors of the mammalian target rapamycin (mTOR). In a phase III study previously untreated, poor-prognosis, advanced renal cell carcinoma (ARCC), mTOR inhibitor temsirolimus improved survival compared interferon. We performed retrospective, independent, blinded radiographic review chest computed tomography (CT) images this to characterize temsirolimus-related pneumonitis. Patients and Methods were intravenous 25 mg once weekly or...
Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is need to improve the clinical understanding and treatment of this disease, particularly in real-world setting among patients who are under-represented trials. We aimed evaluate characteristics outcomes received their first for metastatic castration-resistant (mCRPC) routine practice, independent used, including subgroups with baseline cardiac diabetes mellitus, or visceral metastases....
5012 Background: Cisplatin-based neoadjuvant chemotherapy (CT) followed by radical cystectomy (RC) is a standard treatment for MIBC. PD-1/L1 inhibitors as single agent induce pathological complete responses (pCR) in this setting. Predictors of response are still ill defined. DUTRENEO trial aimed to prospectively explore the activity anti-PDL1 + anti-CTLA4 vs CT pts selected according tumor pro-inflammatory IFN-gamma signature (tumor immune score, TIS). Methods: Cisplatin-eligible with...